{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:18:51Z","timestamp":1761513531756},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,10,8]],"date-time":"2014-10-08T00:00:00Z","timestamp":1412726400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s00280-014-2589-3","type":"journal-article","created":{"date-parts":[[2014,10,7]],"date-time":"2014-10-07T08:28:08Z","timestamp":1412670488000},"page":"1149-1157","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy\/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902"],"prefix":"10.1007","volume":"74","author":[{"name":"Hokkaido Lung Cancer Clinical Study Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenya","family":"Kanazawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yokouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xintao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Fujiuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Takamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Oizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Katsuura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Honjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotoshi","family":"Dosaka-Akita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Munakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaharu","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,10,8]]},"reference":[{"key":"2589_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Farley J, Ward E, Frorman D (2011) Global cancer statistics. CA Cancer J Clin 61:69\u201390","journal-title":"CA Cancer J Clin"},{"key":"2589_CR2","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1200\/JCO.2008.17.7162","volume":"26","author":"NSCLC Meta-Analyses Collaborative Group","year":"2008","unstructured":"NSCLC Meta-Analyses Collaborative Group (2008) Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 26:4617\u20134625","journal-title":"J Clin Oncol"},{"key":"2589_CR3","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/cncr.22478","volume":"109","author":"K Hotta","year":"2007","unstructured":"Hotta K, Fujiwara Y, Matsuo K, Suzuki T, Kiura K, Tabata M, Takigawa N, Ueoka H, Tanimoto M (2007) Recent improvement in the survival of patients with advanced non-small-cell lung cancer enrolled in phase III trials of first-line systemic chemotherapy. Cancer 109:939\u2013948","journal-title":"Cancer"},{"key":"2589_CR4","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","volume":"26","author":"GV Scagliotti","year":"2008","unstructured":"Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-na\u00efve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543\u20133551","journal-title":"J Clin Oncol"},{"key":"2589_CR5","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1023\/A:1008336931378","volume":"11","author":"C Manegold","year":"2000","unstructured":"Manegold C, Gatzemeier U, von Pawel J, Pirker R, Malayeri R, Blatter J, Krejcy K (2000) Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: A multicenter phase II trial. Ann Oncol 11:435\u2013440","journal-title":"Ann Oncol"},{"key":"2589_CR6","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.lungcan.2011.10.021","volume":"76","author":"J Treat","year":"2012","unstructured":"Treat J, Scagliotti GV, Peng G, Monberg MJ, Obasaju CK, Socinski MA (2012) Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of three phase 3 trials. Lung Cancer 76:222\u2013227","journal-title":"Lung Cancer"},{"key":"2589_CR7","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.3747\/co.19.891","volume":"19","author":"K Al-Saleh","year":"2012","unstructured":"Al-Saleh K, Quinton C, Ellis PM (2012) Role of pemetrexed in advanced non-small-cell lung cancer: meta-analysis of randomized controlled trials, with histology subgroup analysis. Curr Oncol 19:e9\u2013e15","journal-title":"Curr Oncol"},{"key":"2589_CR8","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/1097-0142(20010801)92:3<595::AID-CNCR1359>3.0.CO;2-D","volume":"92","author":"FA Shepherd","year":"2001","unstructured":"Shepherd FA, Dancey J, Arnold A, Neville A, Rusthoven J, Johnson RD, Fisher B, Eisenhauer E (2001) Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: A study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 92:595\u2013600","journal-title":"Cancer"},{"key":"2589_CR9","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1200\/JCO.2008.20.9114","volume":"27","author":"BH Gr\u00f8nberg","year":"2009","unstructured":"Gr\u00f8nberg BH, Bremnes RM, Fl\u00f8tten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Toll\u00e5li T, Wammer F, Aaseb\u00f8 U, Sundstr\u00f8m S (2009) Phase III study by the Norwegian Lung Cancer Study Group: Pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non\u2013small-cell lung cancer. J Clin Oncol 27:3217\u20133224","journal-title":"J Clin Oncol"},{"key":"2589_CR10","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1002\/cncr.21480","volume":"104","author":"RG Zinner","year":"2005","unstructured":"Zinner RG, Fossella FV, Gladish GW, Glisson BS, Blumenschein GR Jr, Papadimitrakopoulou VA, Pisters KM, Kim ES, Oh YW, Peeples BO, Ye Z, Curiel RE, Obasaju CK, Hong WK, Herbst RS (2005) Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced non-small cell lung cancer. Cancer 104:2449\u20132456","journal-title":"Cancer"},{"key":"2589_CR11","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1200\/JCO.2004.02.109","volume":"22","author":"K Hotta","year":"2004","unstructured":"Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M (2004) Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 22:3852\u20133859","journal-title":"J Clin Oncol"},{"key":"2589_CR12","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/nrd1528","volume":"3","author":"M Muhsin","year":"2004","unstructured":"Muhsin M, Gricks C, Kirkpatrick P (2004) Pemetrexed disodium. Nat Rev Drug Discov 3:825\u2013826","journal-title":"Nat Rev Drug Discov"},{"key":"2589_CR13","first-page":"4455","volume":"25","author":"A Takehara","year":"2005","unstructured":"Takehara A, Kawakami K, Ohta N, Oyama K, Ota Y, Oda M, Watanabe G (2005) Prognostic significance of the polymorphisms in thymidylate synthase and methylenetetrahydrofolate reductase gene in lung cancer. Anticancer Res 25:4455\u20134462","journal-title":"Anticancer Res"},{"key":"2589_CR14","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/sj.tpj.6500320","volume":"5","author":"JG Maring","year":"2005","unstructured":"Maring JG, Groen HJ, Wachters FM, Uges DR, de Vries EG (2005) Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J 5:226\u2013243","journal-title":"Pharmacogenomics J"},{"key":"2589_CR15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/jjco\/hyn121","volume":"39","author":"H Ishihama","year":"2008","unstructured":"Ishihama H, Chida M, Araki O, Karube Y, Seki N, Tamura M, Umezu H, Honma K, Masawa N, Miyoshi S (2008) Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung. Jpn J Clin Oncol 39:33\u201336","journal-title":"Jpn J Clin Oncol"},{"key":"2589_CR16","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.2008.19.1650","volume":"27","author":"EF Smit","year":"2009","unstructured":"Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P, Dingemans AM, Joerger M, Schellens JH, Vincent A, van Zandwijk N, Groen HJ (2009) Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 27:2038\u20132045","journal-title":"J Clin Oncol"},{"key":"2589_CR17","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3816\/CCC.2002.n.003","volume":"1","author":"MG Rose","year":"2002","unstructured":"Rose MG, Farrell MP, Schmitz JC (2002) Thymidylate synthase: a critical target for cancer chemotherapy. Clin Colorectal Cancer 1:220\u2013229","journal-title":"Clin Colorectal Cancer"},{"key":"2589_CR18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.lungcan.2010.10.022","volume":"73","author":"I Okamoto","year":"2011","unstructured":"Okamoto I, Hirabayashi N, Kitano M, Nakagawa K (2011) Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer. Lung Cancer 73:103\u2013109","journal-title":"Lung Cancer"},{"key":"2589_CR19","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1349-7006.2009.01358.x","volume":"101","author":"H Ozasa","year":"2010","unstructured":"Ozasa H, Oguri T, Uemura T, Miyazaki M, Maeno K, Sato S, Ueda R (2010) Significance of thymidylate synthase for resistance to pemetrexed in lung cancer. Cancer Sci 101:161\u2013166","journal-title":"Cancer Sci"},{"key":"2589_CR20","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/annonc\/mdq730","volume":"22","author":"F Tanaka","year":"2011","unstructured":"Tanaka F, Wada H, Fukui Y, Fukushima M (2011) Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population. Ann Oncol 22:1791\u20131797","journal-title":"Ann Oncol"},{"key":"2589_CR21","first-page":"6004","volume":"63","author":"K Kawakami","year":"2003","unstructured":"Kawakami K, Watanabe G (2003) Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 63:6004\u20136007","journal-title":"Cancer Res"},{"key":"2589_CR22","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1200\/JCO.1999.17.1.409","volume":"17","author":"RS Go","year":"1999","unstructured":"Go RS, Adjei AA (1999) Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17:409\u2013422","journal-title":"J Clin Oncol"},{"key":"2589_CR23","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.lungcan.2007.03.014","volume":"57","author":"J Jiang","year":"2007","unstructured":"Jiang J, Liang X, Zhou X, Huang R, Chu Z (2007) A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 57:348\u2013358","journal-title":"Lung Cancer"},{"key":"2589_CR24","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/jnci\/djk196","volume":"99","author":"A Ardizzoni","year":"2007","unstructured":"Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, Radosavljevic D, Paccagnella A, Zatloukal P, Mazzanti P, Bisset D, Rosell R, CISCA (CISplatin versus CArboplatin) Meta-analysis Group (2007) Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 99:847\u2013857","journal-title":"J Natl Cancer Inst"},{"key":"2589_CR25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00280-012-1910-2","volume":"70","author":"YH Kim","year":"2012","unstructured":"Kim YH, Hirabayashi M, Togashi Y, Hirano K, Tomii K, Masago K, Kaneda T, Yoshimatsu H, Otsuka K, Mio T, Tomioka H, Suzuki Y, Mishima M (2012) Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902. Cancer Chemother Pharmacol 70:271\u2013276","journal-title":"Cancer Chemother Pharmacol"},{"key":"2589_CR26","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s10637-013-9941-z","volume":"31","author":"I Okamoto","year":"2013","unstructured":"Okamoto I, Aoe K, Kato T, Hosomi Y, Yokoyama A, Imamura F, Kiura K, Hirashima T, Nishio M, Nogami N, Okamoto H, Saka H, Yamamoto N, Yoshizuka N, Sekiguchi R, Kiyosawa K, Nakagawa K, Tamura T (2013) Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-na\u00efve patients with advanced nonsquamous non-small-cell lung cancer. Invest New Drugs 31:1275\u20131282","journal-title":"Invest New Drugs"},{"key":"2589_CR27","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(12)70063-3","volume":"13","author":"L Paz-Ares","year":"2012","unstructured":"Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C (2012) Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomized controlled trial. Lancet Oncol 13:247\u2013255","journal-title":"Lancet Oncol"},{"key":"2589_CR28","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1634\/theoncologist.1-1-68","volume":"1","author":"CH Takimoto","year":"1996","unstructured":"Takimoto CH (1996) New antifolates: pharmacology and clinical applications. Oncologist 1:68\u201381","journal-title":"Oncologist"},{"key":"2589_CR29","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1634\/theoncologist.6-4-363","volume":"6","author":"AR Hanauske","year":"2001","unstructured":"Hanauske AR, Chen V, Paoletti P, Niyikiza C (2001) Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 6:363\u2013373","journal-title":"Oncologist"},{"key":"2589_CR30","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/cncr.21777","volume":"106","author":"H Hashimoto","year":"2006","unstructured":"Hashimoto H, Ozeki Y, Sato M, Obara K, Matsutani N, Nakagishi Y, Ogata T, Maehara T (2006) Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung. Cancer 106:1595\u20131601","journal-title":"Cancer"},{"key":"2589_CR31","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s12032-011-0069-8","volume":"29","author":"K Kaira","year":"2012","unstructured":"Kaira K, Ohde Y, Nakagawa K, Okumura T, Murakami H, Takahashi T, Kondo H, Nakajima T, Endo M, Yamamoto N (2012) Thymidylate synthase expression is closely associated with outcome in patients with pulmonary adenocarcinoma. Med Oncol 29:1663\u20131672","journal-title":"Med Oncol"},{"key":"2589_CR32","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/ijc.27338","volume":"131","author":"MS Lee","year":"2012","unstructured":"Lee MS, Asomaning K, Su L, Wain JC, Mark EJ, Christiani DC (2012) MTHFR polymorphisms, folate intake and carcinogen DNA adducts in the lung. Int J Cancer 131:1203\u20131209","journal-title":"Int J Cancer"},{"key":"2589_CR33","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/carcin\/bgm104","volume":"28","author":"T Suzuki","year":"2007","unstructured":"Suzuki T, Matsuo K, Hiraki A, Saito T, Sato S, Yatabe Y, Mitsudomi T, Hida T, Ueda R, Tajima K (2007) Impact of one-carbon metabolism-related gene polymorphisms on risk of lung cancer in Japan: a case control study. Carcinogenesis 28:1718\u20131725","journal-title":"Carcinogenesis"},{"key":"2589_CR34","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.lungcan.2007.12.001","volume":"61","author":"H Liu","year":"2008","unstructured":"Liu H, Jin G, Wang H, Wu W, Liu Y, Qian J, Fan W, Ma H, Miao R, Hu Z, Sun W, Wang Y, Jin L, Wei Q, Shen H, Huang W, Lu D (2008) Association of polymorphisms in one-carbon metabolizing genes and lung cancer risk: a case-control study in Chinese population. Lung Cancer 61:21\u201329","journal-title":"Lung Cancer"},{"key":"2589_CR35","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/1471-2407-6-257","volume":"6","author":"DN Martin","year":"2006","unstructured":"Martin DN, Boersma BJ, Howe TM, Goodman JE, Mechanic LE, Chanock SJ, Ambs S (2006) Association of MTHFR gene polymorphism with breast cancer survival. BMC Cancer 6:257","journal-title":"BMC Cancer"},{"key":"2589_CR36","doi-asserted-by":"crossref","first-page":"578","DOI":"10.2174\/138920210793360925","volume":"11","author":"BS Askari","year":"2010","unstructured":"Askari BS, Krajinovic M (2010) Dihydrofolate reductase gene variations in susceptibility to disease and treatment outcomes. Curr Genomics 11:578\u2013583","journal-title":"Curr Genomics"},{"key":"2589_CR37","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.lungcan.2011.01.024","volume":"74","author":"CY Chen","year":"2011","unstructured":"Chen CY, Chang YL, Shih JY, Lin JW, Chen KY, Yang CH, Yu CJ, Yang PC (2011) Thymidylate synthase and dehydrofolate reductase expression in non-small cell lung cancer: the association with treatment efficacy of pemetrexed. Lung Cancer 74:132\u2013138","journal-title":"Lung Cancer"},{"key":"2589_CR38","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.2012.48.1911","volume":"31","author":"M Zukin","year":"2013","unstructured":"Zukin M, Barrios CH, Pereira JR, Ribeiro RDA, Beato CA, do Nascimento YN, Murad A, Franke FA, Precivale M, Araujo LH, Baldotto CS, Vieira FM, Small IA, Ferreira CG, Lilenbaum RC (2013) Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol 31:2849\u20132853","journal-title":"J Clin Oncol"},{"key":"2589_CR39","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(11)60780-0","volume":"378","author":"E Quoix","year":"2011","unstructured":"Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavol\u00e9 A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Dansin E, Poudenx M, Molinier O, Vaylet F, Moro-Sibilot D, Herman D, Bennouna J, Tredaniel J, Ducolon\u00e9 A, Lebitasy MP, Baudrin L, Laporte S, Milleron B, Intergroupe Francophone de Canc\u00e9rologie Thoracique (2011) Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet Oncol 378:1079\u20131088","journal-title":"Lancet Oncol"},{"key":"2589_CR40","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.lungcan.2013.01.008","volume":"80","author":"R Gervais","year":"2013","unstructured":"Gervais R, Robinet G, Cl\u00e9ment-Duch\u00eane C, Denis F, El Kouri C, Martin P, Chouaki N, Bourayou N, Mor\u00e8re JF (2013) Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell\u00a0lung cancer\u00a0(NSCLC): a phase II trial. Lung Cancer 80:185\u2013190","journal-title":"Lung Cancer"},{"key":"2589_CR41","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T, North-East Japan Study Group (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. Engl J Med 362:2380\u20132388","journal-title":"Engl J Med"},{"key":"2589_CR42","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","volume":"11","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M, West Japan Oncology Group (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 11:121\u2013128","journal-title":"Lancet Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2589-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2589-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2589-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T01:21:03Z","timestamp":1650331263000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2589-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,8]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["2589"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2589-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2014,10,8]]}}}